ClearNote Health raised $52 million in Series D financing, bringing total funding to more than $185 million. The round was led by founding investor Mattias Westman and included participation from Sandy Weill, ClearNote cofounder Stephen Quake, and other international and institutional investors. ClearNote plans to use the new capital to support clinical studies, expand commercial reach, and develop its Avantect early cancer detection tests and Virtuoso epigenomic platform. The company also highlighted data from an Avantect pancreatic cancer test showing 82.6% sensitivity for early cancer detection. The funding is a near-term accelerant for companies trying to move blood-based early detection toward scalable clinical validation and broader market adoption. Investors will look for whether ClearNote can extend performance from study settings into real-world cohort outcomes.